GTHX Gross Profit from 2010 to 2024
| GTHX Stock | USD 3.77 0.05 1.34% |
Gross Profit | First Reported 2015-12-31 | Previous Quarter 9.2 M | Current Value 13.6 M | Quarterly Volatility 18.5 M |
Check G1 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GTHX main balance sheet or income statement drivers, such as Depreciation And Amortization of 291.2 K, Interest Expense of 10.5 M or Selling General Administrative of 46.9 M, as well as many exotic indicators such as Price To Sales Ratio of 1.82, Dividend Yield of 0.0 or PTB Ratio of 3.32. GTHX financial statements analysis is a perfect complement when working with G1 Therapeutics Valuation or Volatility modules.
GTHX | Gross Profit |
Latest G1 Therapeutics' Gross Profit Growth Pattern
Below is the plot of the Gross Profit of G1 Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of G1 Therapeutics minus its cost of goods sold. It is profit before G1 Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. G1 Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in G1 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 47.55 M | 10 Years Trend |
|
Gross Profit |
| Timeline |
GTHX Gross Profit Regression Statistics
| Arithmetic Mean | 7,150,312 | |
| Coefficient Of Variation | 590.41 | |
| Mean Deviation | 32,125,898 | |
| Median | (3,976,423) | |
| Standard Deviation | 42,216,466 | |
| Sample Variance | 1782.2T | |
| Range | 149.8M | |
| R-Value | 0.59 | |
| Mean Square Error | 1260.1T | |
| R-Squared | 0.34 | |
| Significance | 0.02 | |
| Slope | 5,532,361 | |
| Total Sum of Squares | 24951.2T |
GTHX Gross Profit History
Other Fundumenentals of G1 Therapeutics
G1 Therapeutics Gross Profit component correlations
Click cells to compare fundamentals
About G1 Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include G1 Therapeutics income statement, its balance sheet, and the statement of cash flows. G1 Therapeutics investors use historical funamental indicators, such as G1 Therapeutics's Gross Profit, to determine how well the company is positioned to perform in the future. Although G1 Therapeutics investors may use each financial statement separately, they are all related. The changes in G1 Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on G1 Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on G1 Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in G1 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Gross Profit | 75.3 M | 79.1 M | |
| Gross Profit Margin | 0.91 | 0.96 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of G1 Therapeutics Correlation against competitors. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.